dyspepsia/stroke

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 81 rezilta yo

[Elongated needle for post-stroke indigestion].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To observe the clinical efficacy difference among elongated needle, filiform needle and medication for post-stroke indigestion. METHODS Sixty cases of post-stroke indigestion were randomly assigned into an elongated needle group, a filiform needle group and a medication group, 20 cases in

I had a mild stroke two years ago, but recovered completely and am now healthy and active. After my stroke, my doctor prescribed a statin medication, even though I don't have heart disease. The medication gives me indigestion. Can I stop it without any problems?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of proton pump inhibitors (PPIs) reduces the risks of these digestive

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding. We conducted a multicenter early implementation study to prospectively evaluate the safety, efficacy and adherence to dabigatran for

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Warfarin is the only oral anticoagulant recommended for the prevention of ischemic stroke in atrial fibrillation. A newer and safer anticoagulant is needed because of increased hemorrhagic risks with warfarin, difficult-to-maintain therapeutic levels, and higher drug to drug and food

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively

A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks of intracerebral haemorrhage with warfarin among Asians, there is little published data on dabigatran to assess 'real world' efficacy and safety of dabigatran therapy in Asia. This was a retrospective

Spotlight on dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The need for safe, effective and easily administered and monitored antithrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor

Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The need for safe, effective, and easily administered and monitored antithrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor

Dyspepsia and disease burden among patients with atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This retrospective, observational study was conducted to determine overlap of prevalence between atrial fibrillation (AF), an increasingly common condition that primarily affects the elderly population, and dyspepsia, which is also common. Because the overlap of these conditions could interfere with

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This article provides an overview of the clinical profile of oral dabigatran etexilate (Pradaxa®, Pradax™) [hereafter referred to as dabigatran] when used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), followed by a review of cost-utility

Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Although dyspepsia is common among nonvalvular atrial fibrillation (NVAF) patients, its impact on patient health and cost has not been adequately studied. OBJECTIVE To evaluate the incremental health care burden associated with dyspepsia among NVAF patients and its impact on warfarin

[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of

Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of dabigatran are freedom from monitoring and less interaction with other drugs and food. It is ideal for patients who

Candida esophagitis with fever alone in a patient with stroke.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Candida esophagitis is a rare disease, but its incidence is higher in patients with impaired immunity due to an underlying disease. Patients with candida esophagitis usually present with lower retrosternal pain or dysphagia, but they are sometimes asymptomatic. Several risk factors,

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye